EUVIMEDEUVIMED entdecken
Systematische Übersicht

Clinical utility and prognostic accuracy of the molecular International Prognostic Scoring System versus Revised International Prognostic Scoring System in myelodysplastic syndromes: A systematic review

Hyomshi Bhavsar

International Journal of Molecular and Immuno Oncology · 05.06.2026 · 11 · 80-85

DOI: 10.25259/ijmio_3_2026 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Molecular and Immuno Oncology, online erschienen am 05.06.2026. Verfasst von Hyomshi Bhavsar. Die Arbeit nennt 24 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The molecular International Prognostic Scoring System (IPSS-M) was introduced to integrate genomic data into Myelodysplastic syndromes risk stratification. We systematically reviewed its performance against the existing standard, the Revised International Prognostic Scoring System (IPSS-R), to evaluate its prognostic utility.

Methods

A Preferred Reporting Items for Systematic Reviews and Meta-analyses-compliant search of PubMed, Embase, and Cochrane was conducted (June 2022–December 2025) for studies validating IPSS-M. Heterogeneity was assessed using the I 2 statistic.

Results

Twelve validation studies were identified. The IPSS-M significantly outperformed the IPSS-R in prognostic discrimination, with a concordance index (C-index) for overall survival of 0.81 versus 0.71, and demonstrated high accuracy in predicting acute myeloid leukemia (AML) transformation (C-index 0.91). However, heterogeneity across cohorts regarding sequencing depth and treatment eras was noted.

Conclusion

IPSS-M provides superior risk discrimination, particularly for patients previously classified as “Intermediate” risk by IPSS-R. While promising as an advanced prognostic tool, prospective validation is required to confirm its role in guiding therapeutic interventions.

Zitieren

APA

Bhavsar, H. (2026). Clinical utility and prognostic accuracy of the molecular International Prognostic Scoring System versus Revised International Prognostic Scoring System in myelodysplastic syndromes: A systematic review. International Journal of Molecular and Immuno Oncology, 11, 80-85. https://doi.org/10.25259/ijmio_3_2026

Vancouver

Bhavsar H. Clinical utility and prognostic accuracy of the molecular International Prognostic Scoring System versus Revised International Prognostic Scoring System in myelodysplastic syndromes: A systematic review. International Journal of Molecular and Immuno Oncology. 2026;11:80-85. doi:10.25259/ijmio_3_2026

BibTeX
@article{Bhavsar2026,
  author = {Bhavsar, Hyomshi},
  title = {Clinical utility and prognostic accuracy of the molecular International Prognostic Scoring System versus Revised International Prognostic Scoring System in myelodysplastic syndromes: A systematic review},
  journal = {International Journal of Molecular and Immuno Oncology},
  year = {2026},
  volume = {11},
  pages = {80--85},
  doi = {10.25259/ijmio_3_2026}
}
Kostenlos starten →